Literature DB >> 12966511

Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.

Brigette B Y Ma1, Terence C W Poon, K F To, Benny Zee, Frankie K F Mo, Charles M L Chan, Stephen Ho, Peter M L Teo, Phillip J Johnson, Anthony T C Chan.   

Abstract

BACKGROUND: This study prospectively examines the prognostic role of p53 oncoprotein (p53), Ki67-antigen (Ki67), tumor angiogenesis (MVD), epidermal growth factor receptor (EGFR), and HER2 receptor protein (HER2) expression in Chinese with undifferentiated nasopharyngeal carcinoma (NPC).
METHODS: Seventy-eight Chinese were recruited from October 1995 to July 1997 at the Prince of Wales Hospital, Hong Kong. Pretreatment immunohistochemical preparations of the primary tumor were made, and clinical data were collected prospectively until October 30, 2000. The markers were correlated with overall survival (OS), disease-free survival (DFS), time to progression (TTP), and UICC stage.
RESULTS: On univariate analysis, EGFR expression correlated with poorer OS (p =.0001), DFS (p =.01), shorter TTP (p =.0001), and advanced T stage (p =.036). Strong EGFR expression, when compared with weak or moderate, was associated with poorer OS (p =.04) and shorter TTP in a subgroup of patients with UICC stage III-IV disease. HER2 expression was associated with advanced UICC stage (p =.006). The presence of p53 expression correlated with poorer DFS (p =.01) and a trend toward shorter TTP (p =.06). No correlation was found with Ki67-antigen or MVD. On multivariate analysis, only EGFR expression was significantly linked to shorter OS and TTP.
CONCLUSIONS: EGFR expression in undifferentiated NPC is associated with a poor clinical outcome. A prognostic role of p53 and HER2 expression is suggestive but not consistently defined in this study. The relatively high prevalence of positive staining for EGFR supports the use of molecular targeted therapy in this disease. Copyright 2003 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12966511     DOI: 10.1002/hed.10307

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  61 in total

Review 1.  Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Authors:  Tao Xu; J Tang; M Gu; L Liu; W Wei; H Yang
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

2.  Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.

Authors:  Vivian Wai Yan Lui; Cecilia Pik Yuk Lau; Kakiu Ho; Margaret Heung Ling Ng; Suk Hang Cheng; Sai-Wah Tsao; Chi Man Tsang; Kenny Ieng Kit Lei; Anthony Tc Chan; Tony Shu Kam Mok
Journal:  Invest New Drugs       Date:  2010-06-23       Impact factor: 3.850

3.  Evaluation of the prognostic value of TGF-β superfamily type I receptor and TGF-β type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays.

Authors:  Wenling Zhang; Zhaoyang Zeng; Songqing Fan; Jieru Wang; Jianbo Yang; Yanhong Zhou; Xiayu Li; Donghai Huang; Fang Liang; Minghua Wu; Ke Tang; Li Cao; Xiaoling Li; Wei Xiong; Guiyuan Li
Journal:  J Mol Histol       Date:  2012-03-06       Impact factor: 2.611

4.  Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Hui-Xia Feng; Su-Ping Guo; Gui-Rong Li; Wen-Huan Zhong; Liu Chen; Li-Ru Huang; Hui-Ying Qin
Journal:  Med Oncol       Date:  2014-08-15       Impact factor: 3.064

5.  Phase I study of icotinib, an EGFR tyrosine kinase inhibitor combined with IMRT in nasopharyngeal carcinoma.

Authors:  Wei Hu; Wei Wang; Peinong Yang; Chao Zhou; Weifang Yang; Bo Wu; Hongsheng Lu; Haihua Yang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 6.  HER2 as a therapeutic target in head and neck squamous cell carcinoma.

Authors:  Netanya I Pollock; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

7.  Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Authors:  Edwin Pun Hui; Vivian W Y Lui; Cesar S C Wong; Brigette B Y Ma; Cecilia P Y Lau; Crystal S F Cheung; Kakiu Ho; Suk-Hang Cheng; Margaret H L Ng; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2010-05-15       Impact factor: 3.850

8.  Prognostic analysis of patients with locally advanced nasopharyngeal carcinoma following intensity modulated radiation therapy.

Authors:  Yajie Zhao; Lin Shen; Xinqiong Huang; Yuxiang He; Jun Fu; Yujie Qian; Shan Li; Na Zhao; Liangfang Shen
Journal:  Oncol Lett       Date:  2018-01-24       Impact factor: 2.967

9.  Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Xiaoshuang Niu; Chaosu Hu; Lin Kong
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-24       Impact factor: 4.553

10.  Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response.

Authors:  Brigette B Y Ma; Vivian W Y Lui; Fan Fong Poon; S C Cesar Wong; Ka Fai To; Elaine Wong; Honglin Chen; Kwok Wai Lo; Qian Tao; Anthony T C Chan; Margaret Heung Ling Ng; Suk Hang Cheng
Journal:  Invest New Drugs       Date:  2009-09-16       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.